221 results on '"Chamulitrat, W."'
Search Results
2. Macrophage-specific iPla2β deletion worsens hepatic inflammation in MCD-induced NASH by increasing M1/M2 activation.
3. Macrophage-specific Fatp4 deletion exacerbates HFHC-induced NASH via a shift towards M2 polarization
4. Macrophage-specific Pla2G6 deficiency modulates bone marrow Ly6C levels and APAP liver injury in a sex-dependent manner
5. Intestinal deletion of fatty acid transport protein 4 in mice increases blood chylomicrons
6. Deletion of fatty acid transport protein 4 in HepG2 cells increases lipolysis lipids and lipoprotein secretion
7. Liver specific-deletion of FATP4 increases hepatic triglycerides upon D8-glycerol administration: a stable isotope labelling study
8. Externalization of phosphatidylethanolamine in hepatocytes from male mice is increased by iPLA2β deficiency associated with cellular oxidative stress
9. iPLA2beta Deficiency in mice fed methionine-choline-deficient diet does not protect hepatic steatosis but still attenuates hepatic fatty acids, cholesterol esters, and liver enzymes
10. Phospho- and sphingolipid metabolism is altered in hereditary hemochromatosis independent of iron content and PNPLA3 polymorphism
11. iPLA2b Deficiency Exacerbates an Increase of Bile Acids in the Enterohepatic Circulation by Downregulating Hepatic FXR in Mice fed with Methionine-choline-deficient Diet
12. iPLA2beta protects aged male mice from liver fibrosis and intestinal atrophy by modulating phospholipid and enterohepatic bile acid metabolism
13. aP2-specific inactivation of fatty acid transport protein 4 in mice sensitizes hepatic fibrogenesis under methionine and choline-deficient diet
14. iPLA2beta deficiency protects mice from diet-induced obesity and steatosis by replenishing the loss of hepatic phospholipids containing unsaturated fatty acids
15. The bile acid-phospholipid conjugate Ursodeoxycholyl Lysophosphatidylethanolamide (UDCA-LPE) disturbs pro-fibrogenic Integrin and TGFβ signaling
16. The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling
17. Deficiency of calcium-independent phospholipase A2 beta with aging causes biliary epithelial ductular reaction associated with increased bile acids in enterohepatic circulation
18. The bile acid-phospholipid conjugate Ursodeoxycholyl Lysophosphatidylethanolamide (UDCA-LPE) disturbs pro-fibrogenic Integrin and TGFβ signaling
19. Lysophosphatidylcholine (LPC) as central player for control of hepatocellular fatty acid influx
20. Deficiency of Group VIA phospholipase A2 Primes the Cytokine Releases by Kupffer cells and Lymphocytes
21. P0934 : Lysophosphatidylcholine (LPC) as central player for hepatic fat accumulation and inflammation: Implication for pathogenesis of NASH
22. P0442 : UDCA-LPE modulates different signaling pathways involved in hepatic fibrogenesis
23. P1153 : Acute autoimmune hepatitis increases secondary bile acids resulting in intestinal apoptosis, inflammation, and mucositis in group via calcium-independent phospholipase A2 knockout mice
24. P0486 : Hepatic apoptosis influenced by deficiency of group via calcium-independent phospholipase A2 leads to pro-inflammatory response by Kupffer cells
25. Lysophosphatidylcholine (LPC) as central player for hepatic fat accumulation and inflammation: implication for the pathogenesis of NASH
26. UDCA-LPE modulates different signaling pathways involved in hepatic fibrogenesis
27. Deficiency of calcium-independent phospholipase A2 beta in vivo causes systematic inflammation and hepatocellular carcinoma
28. LBP-543 - iPLA2beta protects aged male mice from liver fibrosis and intestinal atrophy by modulating phospholipid and enterohepatic bile acid metabolism
29. O25 DEFICIENCY OF PHOSPHOLIPASE A2BETA ALTERS HEPATIC LIPID METABOLISM AND ATTENUATES STEATOSIS DURING AGING OR LEPTIN DEFICIENCY
30. Hepatic FATP4-deficiency causes alterations in lipid metabolism
31. Protective role of Ursodeoxycholyl Lysophosphatidylethanolamide during hepatic ischemia and reperfusion injury in mice
32. Ursodeoxycholyl Lysophosphatidyletanolamide (UDCA-LPE) modifies aberrant lipid profiles in non-alcoholic fatty liver disease
33. Deficiency of group via Phospholipase A2 in OB/OB mice renders protection against hepatic steatosis by reduction of VLDL secretion and alteration of phospholipid fatty acid composition
34. Phospholipase A2 controls fatty acid uptake into liver cells in a pharmacologically-responsive way
35. 1253 ATTENUATION OF ADIPOSITY AND HEPATIC STEATOSIS BY GROUP VIA PHOSPHOLIPASE A2 DEFICIENCY IN OB/OB MICE
36. Hemmung der Aktivierung LPS- und IL-6-vermittelter, pro-fibrogener Signalwege in hepatischen Sternzellen durch Ursodeoxycholyl Lysophosphatidylethanolamid (UDCA-LPE)
37. Hepatic hypolipidemia in phospholipase A2 VIA-null mice mediates apoptosis, chronic persistent hepatitis, and sensitivity for autoimmune hepatitis
38. Evaluation for oral use of Ursodeoxycholyl Lysophosphatidylethanolamide (UDCA-LPE): Effective resorption of sodium salt UDCA-LPE
39. Deficiencies of iPLA2beta
40. FATP4 stimulates JNK activation via ER stress and Rac1/MLK3/p-MKK7 signaling leading to enhanced lipoapoptosis
41. 1221 URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE GENERATES HEPATOPROTECTIVE CONJUGATED UDCA, PHOSPHATIDYLCHOLINE, MEDIUM-CHAIN FATTY ACIDS AND PLASMALOGEN 16:1
42. 20 DEFICIENCIES OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 BETA IN VIVO CAUSES REDUCED SYSTEMIC LIPIDS AND LIPOPROTEINS CONCOMITANT WITH INCREASED HEPATIC APOPTOSIS AND INFLAMMATION
43. Das Gallensäure-Phospholipid-Konjugat Ursodeoxycholyl-Lysophosphatidylethanolamid (UDCA-LPE) vermindert die LPS-vermittelte Inflammation in der Leber
44. FATP 4 beeinflusst die Palmitat induzierte Apoptose durch Veränderung des Lipidstoffwechsels
45. Differentielle Regulation von Genen des hepatischen Lipidmetabolismus durch Ursodeoxycholyl Lysophosphatidylethanolamid in verschiedenen diätetischen Modellen der NAFLD
46. Protection against Cholestasis and Ischemia in vitro by Ursodeoxycholyl Lysophosphatidylethanolamide (UDCA-LPE) is Associated with Upregulation of Anti-apoptotic Proteins
47. Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) Generates Hepatoprotective conjugated UDCA, Phosphatidylcholine, Medium-chain Fatty acids and Plasmalogen 16: 1
48. Ursodeoxycholyl Lysophosphatidylethanolamid (UDCA-LPE) hemmt die Hepatofibrogenese durch Inhibition des TGFβ1/Smad-Signalweges in Leberzellen und hepatischen Sternzellen
49. FATP4 verstärkt die Sensibilisierung gegenüber der Lipoapoptose durch eine verminderte Veresterung von Fettsäuren zu Plasmalogen
50. 117 THE BILE ACID PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE EXERTS ANTI-FIBROGENIC EFFECTS AND INHIBITS EPITHELIAL-TO-MESENCHYMAL TRANSITION BY BLOCKING TGFβ1/SMAD2/3 SIGNALING
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.